StemCell Therapy

For decades, two costly medical conditions have been rising on similar trajectories in America: obesity and type 2 diabetes (T2D). Over the last 40 years, adult obesity rates have more than doubled, with a similar rise in individuals with T2D. The link between these two conditions is further suggested by the fact that 70 percent of Americans are now living with obesity or overweight, and 90 percent of all T2D patients have obesity or overweight.

We also know there are strong medical connections between obesity and T2D. As an individuals BMI (body mass index) rises, their risk of developing prediabetes and type 2 diabetes also increases. This is especially true with increases in visceral, or abdominal, fat which is less responsive to insulin. The first line of treatment for T2D generally focuses on glycemic control, often with medications that promote weight gain.

Examining the connection between weight and T2D gives reason to look at more than glycemic control.

Going Beyond Simply Controlling Glucose Levels

Addressing obesity for patients with diabetes, however, enables the clinician to do more than simply control glucose levels: they can treat the underlying insulin resistance that drives T2D. Choosing medications that promote weight loss like GLP-1 agonists and SGLT-2 inhibitors over medications that promote weight gain like insulin and sulfonylureas can improve weight status providing added benefit to diabetes treatment. Unfortunately,two-thirds of people with obesity remain undiagnosed. Medical professionals cite lack of time as a major reason for why they dont discuss weight treatments with their patients, although patients who do receive obesity counselling from physicians trained in obesity medicine report receiving a higher quality of care.

More informed and effective obesity care translates to better diabetes prevention and care. Clinicians evaluating treatment for T2D should also consider obesity treatments ranging from lifestyle interventions to anti-obesity medications to bariatric surgery. For example, the risk of diabetes is reduced by 58 percent with a five to ten percent reduction of weight through lifestyle changes.

A Range of Cost-Effective Interventions

Bariatric surgery, typically associated with obesity treatment, can offer significant benefits for patients with T2D. Noted as a cost-effective intervention by the International Diabetes Foundation, bariatric surgery results in remission for most patients with T2D. Recently,a study published in the New England Journal of Medicine, compared an intensive lifestyle intervention to bariatric surgery and found similar improvements in weight loss and metabolic profile in patients with T2D.

All clinicians can guide patients towards better health outcomes when they understand the connection between obesity and diabetes. The Obesity Medicine Association(OMA) offers a wealth of resources that can help advance that understanding, including specialized continuing education tracks focused on managing adiposity-related diseases and the role of weight management in the treatment of diabetes.OMAs virtual fall conference, OvercomingObesity 2020, will highlight the latest research and best practices related to obesity. Additional OMA resources include The Obesity Algorithm, Obesity Treatment Proficiency Badges and American Board of Obesity Medicine (ABOM) preparation materials.

Health care professionals who embrace an approach to T2D treatment through medical, surgical and especially combined obesity interventions have the potential to make meaningful improvements for patients on multiple fronts.

For more obesity medicine resources or to become an OMA member, visit:www.obesitymedicine.org.

Nicholas Pennings, DO is board certified in Family Medicine and Obesity Medicine and is a fellow of the Obesity Medicine Association (OMA). He is an associate professor and chair of family medicine at Campbell University School of Osteopathic Medicine (CUSOM) and also serves as the director of the Campbell University Health Center. As a champion for advancing the education of current and future health professionals, particularly as it relates to obesity, Dr. Pennings is an executive director of clinical education for the Obesity Medicine Association. He has also infused obesity education into the medical school curriculum at CUSOM and has developed an online obesity education rotation through the OMA for clinicians in training.

Read the original here:
Improve diabetes prevention and care through obesity treatment - Medical Economics

Diabetes mellitus is an increasingly common disease in the United States and is one of the leading causes of death. It is more than just elevated glucose levels. Type 2 diabetes mellitus, as part of the metabolic syndrome, is often accompanied by obesity, hyperlipidemia and hypertension. It is a complex metabolic disease and is considered a heart disease equivalent.

Diabetes has such a huge impact on cardiovascular health that over a decade ago, the FDA started requiring cardiovascular outcomes data for any new antihyperglycemic drugs. While we have known for many years that improved glycemic control decreased cardiovascular risk, we did not have specific data that any particular drug decreased the incidence of cardiac morbidity or mortality. Now, several newer diabetes drugs have been shown to decrease the risk of either hospitalization due to cardiac events or cardiac death. This has changed the way pharmaceutical companies have been marketing their drugs and it has changed the way people look at diabetes.

People other than endocrinologists, that is. Endocrinologists have always treated diabetes as a cardiometabolic disease. As a matter of fact, the American Diabetes Associations (ADA) Standards of Medical Care in Diabetes includes a whole section on managing cardiac risk. For years, endocrinologists have been treating hyperlipidemia and hypertension as part and parcel of their diabetes management.

Ask an endocrinologist how many times they have started a patient on a statin after that patient had been told by other physicians that his cholesterol is normal. Or worse, how often another physician stops the patients statin because his level is good. Too many. Ive even had patients refuse statin therapy because their cardiologist told them they dont need it.

Patients with diabetes comprise a large portion of the population that endocrinologists see. There is now a push to create a new specialty, a new fellowship in cardiometabolic medicine. Most endocrinologists Ive communicated with are asking why? Why do we need this new separate fellowship? Isnt this what weve been doing all along?

If the argument is that there arent enough endocrinologists to go around (see my earlier post), then the answer isnt training more people in a different specialty, the answer is creating more endocrinologists. The answer is making endocrinology more attractive to medical students and residents.

Why go into endocrinology when our healthcare system rewards people for procedures and not cognitive work? It is my hope that the new CMS physician fee schedule and the new visit codes will correct some of this. In addition, we need more funding for endocrinology fellowship programs.

Only about 300 new endocrinologists complete training each year, meanwhile 1.5 million new cases of diabetes are diagnosed in the same time frame. Wouldnt it save the healthcare system millions of dollars to better compensate endocrinologists for managing diabetes and its comorbidities in order to decrease the need for cardiac testing and procedures and to prevent hospitalizations for cardiac events?

Diabetes is definitely a cardiometabolic disease. But we dont need a whole other specialty to start managing it. Endocrinologists have been at the front line of this all along.

The rest is here:
Cardiometabolic Health Fellowships: The Answer or Part of the Problem? - Endocrinology Network

Western eating habits have made their way to other countries, and an increase in diabetes is the unfortunate result.

September 5, 2020 by Diabetes Knowledge Leave a Comment

Worldwide rates of diabetes among the 65-plus population are on the rise, and have increased dramatically in the past 40 years. The US, China, and India have the highest rates of diabetes around the world. Diabetes puts seniors at a much higher risk for chronic wounds including life-threatening diabetic foot ulcers.

Diabetic foot ulcers can progress from an irritation on the bottom of the foot to a gangrenous limb. This would require amputation. Amputation, especially in developing countries is a result of diabetic foot ulcers. Wound experts can monitor the feet of diabetic patients for signs of a foot ulcer. Generally starting out as a red sore on the bottom of the foot. But seniors in developing countries dont always have easy access to wound care experts, making diabetes an even bigger threat to their overall quality of life.

A rise in diabetes is costly for any nations healthcare system. Threatening to reverse progress in countries like India and China. In both countries, many seniors rely on family members for care, and dont have access to expert wound care. Experts also estimate that both countries have high rates of undiagnosed cases, meaning that patients could be at risk for diabetic foot ulcers and not know it.

Patients in India are put further at risk for diabetic foot ulcers because of faulty footwear. However, one study found to be the cause of ulcers in one-fifth of patients.

The causes of diabetes in the U.S. are well known fast food and diets high in sugar provide an obvious explanation. But Western eating habits have made their way to other countries, and an increase in diabetes is the unfortunate result. Even in Japan, with a global reputation for a healthy diet, has also seen a dramatic spike in diabetes in the past few decades. This is due in part to the aging population the likelihood of developing diabetes increases with age. Along with the westernization of the Japanese diet.

In the Marshall Islands, a small group of islands near the Philippines, scientists have had a chance to study a dramatic dietary shift in a small population. Today, many locals subsist almost entirely on pre-packaged, imported food. As a result, over a quarter of the adult population suffers from diabetes.

It wasnt always this way. In the past, the Marshallese diet consisted mostly of seafood and local produce, and unsurprisingly, diabetes was practically non-existent. Researchers believe the introduction of white rice into the local diet may have started the trend toward more carbohydrate-rich, processed foods.

What can we learn from countries with especially low rates of diabetes? Italy has one of the lowest rates of diabetes in Europe, which tracks with recent studies. Research suggests that the Mediterranean diet is the best for lowering the risk of diabetes and obesity. A diet rich in healthy fats, in foods like fish and olives, as well as plenty of fresh produce. Seniors in long-term care may not have easy access to Mediterranean cuisine, but keeping those rough guidelines in mind can help seniors in long-term care make healthier choices and keep their diabetes symptoms in check.

Previously published on diabetesknow

*******************************

***

All Premium Members get to view The Good Men Project with NO ADS.

Need more info? A complete list of benefits is here.

*************************Photo credit: istockphoto

See the rest here:
Diabetes Around the World on the Rise? - The Good Men Project

Text Size:A- A+

Bengaluru: An analysis of over 1,30,000 adults from 21 countries over nearly a decade has indicated a high risk of diabetes linked with the consumption of white rice. The risk is most prominent for the South Asian population, according to findings from a new, large-scale, long-term study.

The study was an international collaboration between researchers from various countries including India, China, and Brazil in Asia, North and South America, Africa and Europe.

Led by Bhavadharini Balaji of the Population Health Research Institute, Hamilton Health Sciences and McMaster University, Canada, the study was a part of the institutes Prospective Urban Rural Epidemiology (PURE) project.

The findings were published in the Diabetes Care journal in its September issue.

White rice is milled rice that has its germ (the part that sprouts), bran (hard outer layer), and husk (outer covering) removed. The polishing of rice further results in a bright and shiny appearance. While white rice has an appealing appearance and can be stored longer, the milling and polishing process remove nutrients such as vitamin B.

White rice has been linked to an outbreak of beriberi in Asia, caused by vitamin B-1 deficiency. It also causes the blood sugar levels to spike upon consumption due to its high glycemic index.

Globally, 42.5 crore people currently have diabetes, and this number is expected to increase to 62.9 crore by 2045, according to the International Diabetes Federation.

Studies have alluded to risk of diabetes associated with white rice for a few decades now, although findings have been contradictory. A 2012 study found that each extra serving of white rice increased the risk for diabetes by 11 per cent.

However, findings change depending on which country studies were conducted in. For example, a study of over 45,000 participants in Singapore found no substantial increase in diabetes was associated with white rice consumption.

Most such studies were limited to single countries. To beat this barrier, the authors of the new study extended it to 21 nations Argentina, Bangladesh, Brazil, Canada, Chile, China, Colombia, India, Iran, Malaysia, occupied Palestine territory, Pakistan, Philippines, Poland, South Africa, Saudi Arabia, Sweden, Tanzania, Turkey, United Arab Emirates, and Zimbabwe.

However, the South Asian population seems to show a pattern with white rice consumption and diabetes, despite a number of other lifestyle factors that increase the disease risk.

South Asians are genetically more predisposed to get diabetes, so there are both lifestyle as well as biological reasons for the high diabetes incidence, said Bengaluru-based physician Dr Gowri Kulkarni.

To understand the link between white rice and diabetes in South Asia, the researchers compared the data from India, Bangladesh, and Pakistan with the rest of the world.

Also read:Unique protein in placenta could hold key to protecting organs from Covid infection

The study involved 132,373 individuals between the ages of 35 and 70, from these 21 countries, who were monitored for nine and a half years. Of these, 6,129 developed diabetes over the course of the study.

Participants were considered if they consumed more than one cup or 150g of cooked rice a day. Overall, the average white rice consumption was 128g a day among the study participants.

However, the team found that the highest consumption of white rice was seen in South Asia at 630g a day, followed by South East Asia at 239g and China at 200g per day. High consumption of rice resulted in lower consumption of other foods like wheat, fibre, red meat, and dairy products.

Carbohydrates make up nearly 80 per cent of calories consumed in many South Asian countries. Since the 1970s, carbs have become increasingly polished and refined as well, losing a lot of nutrition in the process.

Rapid urbanisation and economic development, especially in low- and middle-income countries, have led to a dramatic change in dietary intake and increased physical inactivity, which are related to the obesity epidemic.

Talking about the findings, Mumbai-based nutritionist Priya Kathpal said, I wouldnt say every white rice-eating family would have a diabetic person in their family A lot depends on the quantity of rice eaten, what its eaten with, and how frequently.

Also read:Brainwaves study can tell if a worker can handle crisis situation, IIT Madras research says

China and India are two of the worlds largest countries where rice is the staple food. Both also lead in the incidence of diabetes. However, the researchers found that there wasnt a significant association with white rice consumption and diabetes in China.

There could be many reasons for this, apart from other lifestyle factors. The scientists believe that the kind of rice the Chinese eat (sticky rice) could make a difference.

In India, studies have shown that during the last four to five decades of replacing hand-pounded rice with industrially milled white rice, the prevalence of diabetes in urban areas in India increased from 2 per cent in the 1970s to 25 per cent in 2015, and in rural areas from 1 per cent to 1416 per cent, respectively. White rice is considered to be one of the many main drivers of the trend, which followed improved socioeconomic growth and lifestyle modifications.

Studies have shown that substituting white rice with unpolished brown rice decreases the glycemic response by 23 per cent and the fasting insulin response by 57 per cent in overweight Asian Indians, but consumers do not tend to prefer brown rice due to its inconvenience of longer cooking duration, greater chewing difficulty, and lack of visual appeal.

Several patients that Ive asked to switch to brown rice have faced difficulty, as everyones grown up eating white rice, said Kathpal.

Taste is a huge factor, and brown rice often doesnt taste the same as white with vegetable curries and dals. Sometimes, white rice alternatives like even millets can be more expensive or not as easily available too, she said.

Doctors and dieticians are hesitant to recommend diets that are more expensive and less easily available even if they are healthier, as patients tend not to adopt them successfully.

A daily diet should always be easy to maintain and easily available. Only then can it be sustainable, said Kulkarni. Indians in general have poor protein intake in diet, and this has to do with available resources and choices. Most calories are from carbohydrates as they are cheap.

According to the researchers, in countries where rice is consumed the most or as a staple, the risk of increased diabetes among the public can be lowered by substituting white rice with alternate forms of healthier rice versions and adding more legumes or pulses to food.

Also read:One drink? Or two? Forget the guidelines, less is always better

Subscribe to our channels on YouTube & Telegram

Why news media is in crisis & How you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the medias economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the countrys most robust editing and fact-checking team, finest news photographers and video professionals. We are building Indias most ambitious and energetic news platform. And have just turned three.

At ThePrint, we invest in quality journalists. We pay them fairly. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous and questioning journalism. Please click on the link below. Your support will define ThePrints future.

Support Our Journalism

View post:
White rice linked to diabetes, especially in South Asia, says 21-nation study done over 10 yrs - ThePrint

Cypress resident Anne Imber takes a photo with her son Tristan Edgar, who was diagnosed with Type 1 diabetes in 2009 at the age of 12.

Cypress resident Anne Imber takes a photo with her son Tristan Edgar, who was diagnosed with Type 1 diabetes in 2009 at the age of 12.

Photo: Courtesy Of Anne Imber / Provided By Kimberly Pace, 9th Wonder

Cypress resident Anne Imber takes a photo with her son Tristan Edgar, who was diagnosed with Type 1 diabetes in 2009 at the age of 12.

Cypress resident Anne Imber takes a photo with her son Tristan Edgar, who was diagnosed with Type 1 diabetes in 2009 at the age of 12.

Cypress mother advocates with Beyond Type 1 DKA Campaign to differentiate diabetes symptoms from viruses like COVID-19

Excessive thirst, frequent urination, unexplained weight loss and exhaustion. If Cypress mother Anne Imber and her son had known what these symptoms might indicate, he could have been treated sooner for the serious health complications from his undiagnosed Type 1 diabetes.

Type 1 diabetes is a chronic autoimmune condition that causes the bodys immune system to mistakenly attack the insulin-making beta cells of the pancreas, explained Dr. Daniel DeSalvo, pediatric endocrinologist at Baylor College of Medicine and Texas Childrens Hospital.

Ms. Senior World: Magnolia resident to represent Texas Gulf Coast at inaugural pageant

If a person with diabetes isnt receiving insulin, then they can develop a life-threatening condition called diabetic ketoacidosis, or DKA. It causes stomach pain, nausea, vomiting, tiredness, lethargy, sometimes it can cause rapid or heavy breathing, and if its severe it can lead to the point of confusion or even unconsciousness, DeSalvo said.

DeSalvo is on the science advisory board for Beyond Type 1, a nonprofit focused on building awareness and support for people with Type 1 and Type 2 diabetes worldwide.

Among the organizations initiatives is to prevent the development of DKA by educating people about the warning signs of Type 1 diabetes.

Imber became a Beyond Type 1 volunteer after her sons diabetes diagnosis and has been advocating on behalf of the DKA Campaign.

Texas was actually one of the first states to adopt the Beyond Type 1 DKA Campaign, Imber said. We have a really passionate group of diabetes advocates in the Houston area, and especially in the Cypress area, because we have a Type 1 diabetes school advocacy group.

One factor that can lead to the delayed diagnosis of Type 1 diabetes is the symptom similarities to some viral illnesses such as the flu or a stomach virus, DeSalvo said. During the COVID-19 pandemic, making people aware of Type 1 diabetes telltale symptoms is of vital importance.

On HoustonChronicle.com: Ventilation expert reveals how Texas schools can stop the spread of COVID in classrooms

Its an issue that Imber knows all too well.

Imber said her son Tristan was 12 years old when he and his sister contracted the swine flu in 2009 during the H1N1 pandemic.

My daughter immediately bounced back, Imber said. She was on the mend in two days. My son, he went down with the swine flu and then he never recovered his full energy that hed had before. He started suffering from extreme exhaustion. He started having a lot of weight loss.

There were many factors that Imber thought might be at play he was slimming due to a growth spurt; he had started running cross-country; and, of course, hed just been sick with the swine flu.

He would come home incredibly exhausted, falling asleep, and I really attributed it to the swine flu his recovery from the swine flu just not taking the path that his sister had taken, Imber said.

He continued to go downhill over the next month, losing 20 pounds in just four weeks. Hed tell his mom he was starving but was too nauseous to eat. He became more emotional than usual, Imber said. She knew something was wrong, so she made a Friday appointment with a pediatrician.

They knew immediately how bad it was, but they wanted us to come back Monday morning for a fasting blood glucose (test), she said.

Halloween happened to fall on that weekend. Thank god he did not eat his candy, Imber said. He was waiting for his braces to come off on Tuesday.

By Tuesday morning, his pediatrician had called to relay his diagnosis Type 1 Diabetes.

They realized Tristan had been going into phases of DKA because of his untreated condition.

Because he was running cross-country, his blood sugar would go really high and then it would drop again because of the activity, Imber said. So, it was a really unusual case and thats one of the reasons it took so long to manifest in really obvious terms of, something was seriously wrong.

Imber believes something as simple as an informational poster in the doctors office waiting room, like the ones distributed by the DKA campaign, could have tipped them off sooner.

He hadnt been sharing the excessive thirst and the frequent urination because 12-year-old boys dont do that with their moms; they dont talk about those things, she said. And I know had he been sitting in that office at that time with the DKA Campaign poster there, he would have been able to say, Mom, Ive been having these symptoms and that wouldve really prompted us to get immediate help Friday versus waiting until Tuesday to seek out support for him.

Nowadays, Imber said a DKA diagnosis warrants immediate hospitalization; but at the time, doctors felt the severity level of Tristans condition was low enough to treat him outside of a hospital. Imber said her son was fortunate to not have experienced the organ failure that some do from DKA. She knows of several cases in which lives have been lost because of an incorrect or delayed diagnosis. If her son had not been diagnosed in a timely manner, Imber doesnt doubt he wouldve ended up in the hospital.

We were lucky that he did not incur that seriousness of it, but we immediately saw relief from being able to be treated with the insulin under the care of an endocrinologist, and then started that learning process on how to manage it with the insulin dosing since his pancreas was no longer able to provide that hormone to regulate his food intake, Imber said.

Imber had attributed several of Tristans diabetes symptoms to the residual effects of his flu recovery a relatively common misidentification among people with undiagnosed diabetes, she said.

When its flu season, youll see a lot of people struggling and thinking, It is just the flu, but in reality there are some symptoms that really stand out that frequent urination, that excessive thirst that really differentiate from a flu symptom, Imber said.

The COVID-19 pandemic presents similar challenges for the diagnosis of Type 1 diabetes and DKA, explained Beyond Type 1 Leadership Council Member Michelle Berman.

We are seeing many families protecting themselves and wanting to avoid visits to doctors or the hospital, Berman said. And on top of that, if they arent armed with the knowledge of the warning signs, they also arent taking action when they appear. We really want families to get to the hospital or contact their physician right away, in spite of COVID or in addition to looking for the COVID warning signs. Type 1 diabetes does not stop just because theres a pandemic.

Berman serves as the National Family Advocate for the DKA Campaign.

Her child was diagnosed with Type 1 diabetes in 2007. She took him to the doctor after hed fainted from what she thought was abnormal blood pressure. After his diagnosis, Berman felt frustrated that shed never been made aware of the warning signs for Type 1 diabetes.

Berman learned of the Beyond Type 1 organization in 2016.

So, I partnered with Beyond Type 1 as a family advocate and began working on partnerships with the American Academy of Pediatrics and individual chapters in each state, Berman said. Together, Beyond Type 1 and the AAP partnered and brought awareness to families. Currently, I think theres 25 states across the country that partnered with Beyond Type 1 and disseminated materials warning signs, posters, fliers and handouts to families at well visits.

The campaign began its push to disseminate the information in November of 2016 and has distributed the material in 25 states to more than 28,000 pediatric offices serving over 90 million patients a year, according to Berman.

And thats just phase one.

With a grant from the Helmsley Charitable Trust Foundation, we were able to expand the campaign into phase two, into 10 states across the country, Berman said.

Phase two targets the general public, schools and businesses such as gyms.

In February of this year, the National Association of School Nurses partnered with Beyond Type 1 with the awareness campaign, and so thats been very exciting to expand beyond the pediatricians, Berman said. With the school nurses, were raising awareness of the warning signs, really to be distributed to tens of thousands of school nurses nationally in the United States. So, weve been really thrilled with the awareness and partnerships with this campaign.

For more information or to get involved, visit http://www.beyondtype1.org/dkacampaign or email dka@beyondtype1.org. Find Beyond Type 1 on social media: @beyondtype1.

mfeuk@hcnonline.com

Read more here:
Cypress mother advocates with Beyond Type 1 DKA Campaign to differentiate diabetes symptoms from viruses like COVID-19 - Chron

LEONARDTOWN, MD (September 3, 2020) The St. Marys County Health Department is pleased to announce that the Overdose Response Program, Tobacco Cessation Program and Diabetes Prevention Program will be offered virtually for community members this Fall.

Overdose Response Program

The Overdose Response Program provides free training, open to anyone who would like to learn how opioids affect the body, how to recognize the signs of opioid overdose, and how to care for someone who may be experiencing an overdose until emergency help arrives. Participants can receive an overdose response kit via scheduled curb-side pickup that includes naloxone (Narcan) a life-saving medication that may be able to restore the breathing of someone who has overdosed on opioids.

Next Session: Wednesday, September 30, 2020, from 6:00 7:00 p.m.Learn moreor register at:www.smchd.org/overdose

Tobacco Cessation Program

The Tobacco Cessation Program is free and that takes place over the course of 8 weeks (weekly 1 hour sessions). Participants learn behavioral modifications, stress management, and other techniques to help them quit using tobacco products.

Next Series: Tuesdays, September 15, 2020November 10, 2020 from 5:306:30 p.m. Learn moreor register at:www.smchd.org/tobacco

Diabetes Prevention Program New!

The Diabetes Prevention Program helps participants establish and stick with positive lifestyle changes, such as healthy eating habits, physical activity and positive stress management, which can prevent or delay the onset of Type 2 diabetes. This free program includes 16 weekly sessions, followed by monthly sessions for ongoing support from a lifestyle coach.

Next Series: September 25, 2020 September 24, 2021 from 2:00 3:00 p.m.Learn more or register at:www.smchd.org/dpp

Like Loading...

Related

Visit link:
Virtual Programs Announced for Overdose Response, Tobacco Cessation and Diabetes Prevention - The Southern Maryland Chronicle

Thousands of diabetes patients in the U.K. have been given hope that their illness could be put into remission by a soup-and-shake diet plan being offered by the National Health Service (NHS).

Those with Type 2 diabetes, which is more likely to affect people who are obese or overweight, are being encouraged to take up the low-calorie liquid diet after a trial involving 5,000 people showed that almost half of the participants saw their diabetes go into remission after a year.

Around 12.3 million people in the U.K are at risk of developing Type 2 diabetes, while in the U.S., one-third of Americans could be on their way to developing the disease, with 84 million Americans having pre-diabetes, a condition where people have higher than normal levels of blood sugar, according to the Center for Disease Control (CDC).

Around 10 percent of the U.S. population has diabetes, according to the CDC.

Newsweek subscription offers >

Diabetes is also expected to cost the NHS 10 billion a year.

The year-long diet plan is being offered by the NHS to an initial 10 areas of England and only those who have been diagnosed with the condition in the last six years will be considered for the scheme.

Participants will be provided with diet replacement products such as shakes and soups for three months alongside support with exercise plans as well as managed plans to reintroduce ordinary, nutritious food.

Professor Jonathan Valabhji, NHS national clinical director for diabetes and obesity said: "This is the latest example of how the NHS, through our Long Term Plan, is rapidly adopting the latest evidence-based treatments to help people stay well, maintain a healthy weight and avoid major diseases.

Newsweek subscription offers >

"There has never been a more important time to lose weight and put their Type 2 diabetes into remission, so it's good news for thousands of people across the country that practical, supportive measures like this are increasingly available on the NHS."

It comes as Public Health England data revealed that those with diabetes were more vulnerable to the COVID-19 virus, with a third of people who died in hospital with COVID-19 also having diabetes.

A new study published by the University of North Carolina showed that people with obesity are 113 percent more likely to be admitted to hospital with coronavirus and 74 percent more likely to need intensive care treatment.

Bev, who was one of the first patients to benefit from the diets during trials, said: "My goal for the first eight weeks of the low-calorie diet was to lose 5 percent of my body weight which I achieved in six weeks and in total I've lost over 10kgs, my Type 2 diabetes is now in remission and I no longer have to take any medication I am over the moon.

"Since the low-calorie diet program, my mindset has totally changed for the better and I look at food differently now my shopping habits are far healthier and, when I eat out, I'll go for a healthier option. The program has taught me moderation."

See more here:
Britain Begins Diabetes Trial After 50 Percent Recover Within One Year - Newsweek

For people who are struggling with diabetes, a late-breaking research has found out that it can be prevented or even be reversed by losing weight.

The research was presented on Monday at ESC Congress 2020.

In 2019, approximately 463 million people worldwide had diabetes, of which the vast majority (around 90 per cent) had Type 2 diabetes. It doubles the risk of coronary heart disease, stroke and death from cardiovascular complexities. Obesity is the main modifiable cause of Type 2 diabetes, while genetic make-up may also identify individuals with a greater likelihood of developing the condition.

"Because we are born with our genes, it might be possible to pinpoint early in life who has a high chance of developing diabetes during their lifetime," said principal investigator Professor Brian Ference of the University of Cambridge, UK, and the University of Milan, Italy.

"We conducted this study to find out if combining inherited risk with current body mass index (BMI) could identify people at the highest risk of developing diabetes. Prevention efforts could then concentrate on these individuals," Ference added.

The study included 445,765 participants of the UK Biobank. The average age was 57.2 years and 54 per cent were women. Inherited risk of diabetes was assessed using 6.9 million genes. Height and weight were measured at enrolment to calculate BMI in kg/m2. Participants were divided into five groups according to the GC of diabetes. They were also divided into five groups according to BMI.

Participants were followed-up until an average age of 65.2 years. During that period, 31,298 developed Type 2 diabetes.

Those in the highest BMI group (average 34.5 kg/m2) had an 11-fold increased risk of diabetes compared to participants in the lowest BMI group (average 21.7 kg/m2). The highest BMI group had a greater likelihood of developing diabetes than all other BMI groups, regardless of genetic risk.

"The findings indicate that BMI is a much more powerful risk factor for diabetes that genetic predisposition," said Professor Ference.

The investigators then used statistical methods to estimate whether the likelihood of diabetes in people with a high BMI would be even greater if they were overweight for a long period of time. They found that the duration of elevated BMI did not have an impact on the risk of diabetes.

Professor Ference said: "This suggests that when people cross a certain BMI threshold, their chances of diabetes go up and stay at that same high-risk level regardless of how long they are overweight."

He noted that the threshold is likely different for each person and would be the BMI at which they start to develop abnormal blood sugar levels.

"The findings indicate that most cases of diabetes could be avoided by keeping BMI below the cut-off which triggers abnormal blood sugar. This means that to prevent diabetes, both BMI and blood sugar should be assessed regularly. Efforts to lose weight are critical when a person starts to develop blood sugar problems," said Ference

"It may also be possible to reverse diabetes by losing weight in the early stages before permanent damage occurs," he added.

Continued here:
Diabetes can be prevented, or even be reversed - here's how - DNA India

Prediabetes could lead to type 2 diabetes in future - Know its symptoms and causes  |  Photo Credit: iStock Images

New Delhi: Type 2 diabetes has already reached epidemic levels around the world, with millions of people suffering from the condition. While the condition is very common, it is not completely curable, and can only be managed with the help of a healthy diet, regular physical activity and medicines. At the same time, diabetes can increase the risk of other health conditions like heart and kidney problems, if not managed well. In the wake of the COVID-19 pandemic that the world is struggling with right now, people with diabetes have been listed in the 'high-risk' category for risk of infection and complications due to coronavirus.

While many people know about type 2 diabetes, its causes and symptoms, very few are aware of prediabetes a condition that could be the onset of type 2 diabetes. Here is all you need to know about this condition its symptoms, and causes, and how you can keep yourself safe and healthy.

Prediabetes is a condition where your blood sugar or blood glucose levels are high, but not high enough to be termed as type 2 diabetes.

People who develop type 2 diabetes eventually, have prediabetes first. If prediabetes is not checked, it can transpire into type 2 diabetes within about 10 years, experts suggest. People who have prediabetes are at a high risk of developing type 2 diabetes in their life.

Prediabetes is very common, and it does not necessarily mean that one will suffer from type 2 diabetes. Unlike type 2 diabetes, prediabetes is reversible and can be managed with a healthy diet, regular physical activity, and some lifestyle changes.

While there is no particular cause of type 2 diabetes or prediabetes known, certain factors such as family history, genetics, and lifestyle are known to play a role. Obesity, especially around the abdomen, is considered an important factor for the pancreas to not produce insulin, or for the cells in the organs to not use it.

It is important to understand that prediabetes often does not show any signs or symptoms of the condition. Therefore, regular tests, especially for people who re aware that they are at high risk of developing the condition based on the causes listen above, are extremely vital.

Some uncommon symptoms of prediabetes include -

The bottom line is that a healthy diet comprising of high-fibre, nutrient and mineral-rich food, and a healthy lifestyle that comprises of mindfulness and regular exercise is important to stay healthy and keep the risk of diseases at bay, including prediabetes and type 2 diabetes.

Disclaimer: Tips and suggestions mentioned in the article are for general information purposes only and should not be construed as professional medical advice. Always consult your doctor or a professional healthcare provider if you have any specific questions about any medical matter.

Go here to see the original:
Prediabetes could lead to type 2 diabetes in future - Know its symptoms and causes - Times Now

Coffee can help reduce the risk of developing type 2 diabetes but just filtered coffee, rather than boiled coffee. New research study from Chalmers University of Innovation and Ume University, both in Sweden, show that the option of preparation method influences the health effects of coffee.

Numerous previous studies have actually shown a connection between high coffee intake and a minimized risk of establishing type 2 diabetes. Now, a research study from Chalmers University of Innovation and Ume University, offers new insight into this connection, using an unique approach to help distinguish between the effects of filtered coffee and boiled coffee.

We have identified specific molecules biomarkers in the blood of those taking part in the study, which indicate the intake of different sorts of coffee. These biomarkers are then used for analysis when calculating type 2 diabetes risk. Our results now clearly show that filtered coffee has a positive effect in terms of reducing the risk of developing type 2 diabetes. But boiled coffee does not have this effect, says Rikard Landberg, Professor in Food Science at Chalmers, and Affiliated Professor at the Department of Public Health and Clinical Medicine at Ume University.

With making use of these biomarkers, the researchers had the ability to show that people who drank 2 to 3 cups of filtered coffee a day had a 60% lower threat of establishing type 2 diabetes than people who drank less than one cup of filtered coffee a day. Consumption of boiled coffee had no effect on the diabetes risk in the research study.

Filtered coffee is the most common approach of preparation in many places, including the US and Scandinavia. Boiled coffee in this case refers to an alternative method of coffee preparation often used in Sweden and some other nations, in which coarse ground coffee is simply added straight to boiling water and left to brew for a couple of minutes. All the information used in the research originated from a group of Swedish subjects and was gathered in the early 1990s.

According to Rikard Landberg, many individuals incorrectly think that coffee has only unfavorable impacts on health. This could be since previous research studies have shown that boiled coffee increases the threat of heart and vascular diseases, due to the existence of diterpenes, a type of particle found in boiled coffee.

But it has been shown that when you filter coffee, the diterpenes are captured in the filter. As a result, you get the health benefits of the many other molecules present, such as different phenolic substances. In moderate amounts, caffeine also has positive health effects, he says.

The question is whether diterpenes likewise negatively affect sugar metabolic process and are therefore the cause of why boiled coffee does not help decrease the threat of diabetes, in the way that filter coffee does. The scientists still can not say the specific nature of the link.

Numerous other types of coffee preparation were not specifically examined in the research study, such as instant, espresso, cafetire, and percolator coffee. These kinds of coffee were not typical amongst the Swedish research study population when the data was collected.

However considered that espresso coffee, from traditional espresso machines or the now popular coffee-pods, is also brewed without filters, Rikard Landberg believes the health effects could therefore resemble boiled coffee, in regards to the threat of type 2 diabetes. Coffee made in a cafetire, or French press, is prepared in a comparable method to boiled coffee, so it may also not have the positive impact of reducing type 2 diabetes danger. It is uncertain whether instantaneous coffee, the most popular enter the UK, would be more similar to filtered or boiled coffee in this regard.

However the researchers are careful to note that no conclusions can be drawn yet regarding these other preparation techniques. Rickard Landberg likewise stresses that the health effects of coffee do not depend exclusively on if it is filtered or not. They likewise differ with how the coffee beans, and the drink in general, are handled.

To differentiate the diabetes risk for boiled and filtered coffee, a new strategy called metabolomics was used, in combination with timeless dietary surveys. Metabolomics makes it possible to identify the blood concentration of specific particles from a given food or drink and utilize that as an unbiased measurement of consumption instead of simply depending on self-reported consumptions from the questionnaires, which are prone to big mistakes.

Metabolomics is a fantastic tool, not just for capturing the intake of specific foods and drinks, but also for studying the effects that that intake has on peoples metabolism. We can derive important information on the mechanisms behind how certain foods influence disease risk, says Lin Shi, Postdoctoral researcher and the lead author of the study.

Read the original:
Filtered Coffee can help slow the risk of developing type 2 diabetes - Drew Reports News

One sign to note is having sweet-smelling pee.

A person with uncontrolled diabetes may have blood glucose levels that are dangerously high, and as the body tries to get rid of the extra glucose in the urine it can cause a sweet smell, according to Medical News Today.

The site adds: People with sweet-smelling urine due to diabetes may notice other symptoms, including exhaustion, extreme thirst, appetite changes and unexplained weight loss.

Its important to note other conditions can cause a persons pee to smell.

READ MORE:How to live longer: Consume this spice to reduce heart disease risk and inhibit cancer

Smelly pee accompanied with lower back pain, pain when peeing and blood in pee can be caused by kidney stones, says the NHS.

And smelly pee accompanied by yellow skin and eyes (jaundice, tummy pain, nausea and vomiting can be a sign of liver failure.

But this isnt the only way a persons pee can be affected.

Polyuria is a condition where the body urinates more than usual and can be triggered by Type 2 diabetes.

DON'T MISS

A person may also pass excessive or abnormally large amounts of urine each time they urinate.

Polyuria is defined as the frequent passage of large volumes of urine more than three litres a day compared to the normal daily urine output in adults of about one to two litres, explains Diabetes.co.uk.

It is one of the main symptoms of diabetes (both type 1 and type 2 diabetes) and can lead to severe dehydration, which if left untreated can affect kidney function.

The most common sign of polyuria is producing abnormally large volumes of urine at regular intervals throughout the day and night.

The charity adds: Having some of the signs and symptoms of diabetes doesnt mean you definitely have the condition, but you should always contact your GP, just to make sure.

A healthy diet and keeping active will help you manage your blood sugar level, says the NHS.

It advises you eat a wide range of foods, including fruit, vegetables and some starchy foods like pasta, to keep sugar, fat and salt to a minimum, and to eat breakfast, lunch and dinner every day - do not skip meals.

It also advises you do 2.5 hours of activity a week.

View post:
Type 2 diabetes symptoms: The sign in your urine you could have the chronic condition - Express

Wearing face maskswith reading glasses is now worry-free-thanks to The University of Wisconsin and YouTube's Lennon Rodgers, who posted a do-it-yourself (DIY) hack in his channel that demonstrates the step-by-step procedure for people to create their own 'Badger Seals.' The university's innovation will help prevent hot steam from human breath exiting the mask and fogging-up lenses in the process.

Many people who wear reading and shaded glasses, together with the required face masks, who stroll around the streets and public areas, are bothered by the fog that it causes to the lenses. This fog is bothersome as it requires users to remove and clean the glasses to clear-up vision.

The American Academy of Opthalmology (AAO)recognizes this dilemma for people who wear prescription glasses because this is considered to be a potential danger when walking, driving, and other essential actions are visually impaired due to the lenses' fog.

The University of Wisconsin-Madison College of Engineering releases a reporton the "mask fitters" that prevent people from fogging up their glasses. The university referred to this as the "Badger Seal" and shared the step-by-step procedure on various Open Document sources in Google Slidesand PDFs.

David Rothamer and Scott Sanders spearheaded this design for the public to use and create on their own. The researchers and engineers even provided 3D images available for 3D printing for ease of creation.

ALSO READ: CDC: COVID-19 Vaccines Will Administer on 'Day of the Dead' as Experts Fear the Rush

The Badger Seal is a soft and flexible mask fitter frame that locks the mask in place, significantly improving the cover's seal in a person's face. The currently available face masks are fitted for the general public and do not cater to specific facial shapes.

This leaves some people to have some gaps for air to enter and escape, thus defeating the purpose of protection against viruses, prominently, the Novel coronavirus, or COVID-19.

The University of Wisconsin promises that this design will enhance a 3-layer face mask's protection more effectively. Badger Seals can also be manufactured cheaply and easily by people who have no experience creating various designs.

Here is a rundown of the components needed to create a DIY Badger Seal right at your home's comforts.

Tools:

Materials

The researchers, along with Lennon Rodgers, created instructional videos that demonstrate the Badger Seals' creation and function. There are three types of seals (A, B, and C) to choose from according to your preference and material availability.

The three types of Badger Seals offer the same design of frames but are intended for different face sizes and materials. Type A is designed for the average facial size with the tie-on design, Type B is intended for those with slightly bigger face size (those with beards), and Type C is intended for those who will utilize earloops for easier installation.

ALSO READ: Elon Musk Gets German Minister's Full Support in Trip to Berlin Gigafactory Despite Anti-Tesla Protests

This article is owned by Tech Times

Written by Isaiah Alonzo

2018 TECHTIMES.com All rights reserved. Do not reproduce without permission.

Continue reading here:
WATCH: This Badger Seal Hack Promises a Fog-Free Experience While Wearing Face Masks; Vision Impaired No More - Tech Times

Global Connective Tissue Growth Factor market- Report defines the vital growth factors, opportunities and market segment of top players during the forecast period from 2019 to 2025. The report Connective Tissue Growth Factor offers a complete market outlook and development rate during the past, present, and the forecast period, with concise study, Connective Tissue Growth Factor market effectively defines the market value, volume, price trend, and development opportunities. The comprehensive, versatile and up-to-date information on Connective Tissue Growth Factor market is provided in this report.

The latest research report on Connective Tissue Growth Factor market encompasses a detailed compilation of this industry, and a creditable overview of its segmentation. In short, the study incorporates a generic overview of the Connective Tissue Growth Factor market based on its current status and market size, in terms of volume and returns. The study also comprises a summary of important data considering the geographical terrain of the industry as well as the industry players that seem to have achieved a powerful status across the Connective Tissue Growth Factor market.

For more insights into the Market, request a sample of this report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2550879&source=atm

The following manufacturers are covered:BLR Bio LLCFibroGen IncProMetic Life Sciences IncRXi Pharmaceuticals Corp

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeBLR-200IB-DMDOLX-201PBI-4050Others

Segment by ApplicationHypertrophic ScarsOpthalmologyGenetic DisordersLiver FibrosisOthers

For Information On The Research Approach Used In The Report, Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2550879&source=atm

Complete Analysis of the Connective Tissue Growth Factor Market:

Comprehensive assessable analysis of the industry is provided for the period of 2019-2025 to help investors to capitalize on the essential market opportunities.

The key findings and recommendations highlight vital progressive industry trends in the global Connective Tissue Growth Factor market, thereby allowing players to improve effective long term policies

A complete analysis of the factors that drive market evolution is provided in the report.

To analyze opportunities in the market for stakeholders by categorizing the high-growth segments of the market

The numerous opportunities in the Connective Tissue Growth Factor market are also given.

Note: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

This detailed report on Connective Tissue Growth Factor market largely focuses on prominent facets such as product portfolio, payment channels, service offerings, applications, in addition to technological sophistication. The report lends versatile cues on market size and growth traits, besides also offering an in-depth section on opportunity mapping as well as barrier analysis, thus encouraging report readers to incur growth in global Connective Tissue Growth Factor market.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2550879&licType=S&source=atm

Furthermore, Global Connective Tissue Growth Factor Market following points are involved along with a detailed study of each point:

Generation of this Global Connective Tissue Growth Factor Industry is tested about applications, types, and regions with price analysis of players that are covered.

Revenue, sales are planned for this Connective Tissue Growth Factor market, including with various essentials along yet another facet is assessed in this section for foremost regions.

In continuation using earnings, this section studies consumption, and global Connective Tissue Growth Factor market. This area also sheds light on the variance between ingestion and distribution. Export and Connective Tissue Growth Factor significance data are provided in this part.

In this section, key players have been studied depending on product portfolio, their Connective Tissue Growth Factor market company profile, volume, price, price, and earnings.

Connective Tissue Growth Factor market analysis aside from business, the information, and supply, contact information from manufacturers, consumers and providers can also be presented. Additionally, a feasibility study to asset and SWOT analysis for endeavors have been contained.

For More Information Kindly Contact:

ResearchMoz

Mr. Rohit Bhisey,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Link:
Now Available Connective Tissue Growth Factor Market Forecast And Growth 2019-2025 - thedailychronicle.in

Researchstore.bizhas published an exclusive report named Global Tissue Ablation Market 2020 by Company, Regions, Type and Application, Forecast to 2025which consists of overall market scenario with prevalent and future growth prospects. The report delivers the analytical elaboration and other industry-linked information in an aim to supply specific and reliable analysis on the global Tissue Ablation market. The report focuses on market dynamics, growth-driving factors, restraints, and limitations this market is currently facing and is expected to face in the coming years (2020-2025). The report is further divided by company, by country, and by application/types for the competitive landscape analysis. It estimates production chain, manufacturing capacity, sales volume, and revenue.

The report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive landscape, sales analysis, the impact of domestic and global market players. It contains advanced information associated with the global Tissue Ablation market status, trends analysis, segment, and forecasts from 2020-2025. It explains market scenarios, comparative pricing between major players, cost, and profit of the specified market regions.

NOTE:This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Tissue Ablation market.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/20484

Key Players Analysis:

The report analyzes the top manufacturers, exporters, and retailers (if applicable) around the world concerning their company profile, product portfolio, capacity, price, cost, and revenue. For competitor segment, the report covers the following global Tissue Ablation market key players and some other small players:Boston Scientific, Abbott, Johnson& Johnson, Medtronic

In market segmentation by types, the report covers:Radiofrequency Ablation, Ultrasound Ablation, Laser-Based Ablation, Irreversible Electroporation, Cryoablation Devices, Microwaves Ablation, Hydrothermal Ablation, External Beam Radiation Therapy (EBRT),

In market segmentation by applications, the report covers the following uses:Oncology, Cardiology, Gynecology, Cosmetology, Urology, Opthalmology,

Regionally, this report focuses on several key regions:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East& Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Moreover, the report exhaustively investigates business opportunities, market scope, threats, and barriers. The report aims to help companies in strategizing their decisions in a better way and finally attains their business goals. The research answers important business questions like how the global Tissue Ablation market will perform in the existing market scenario. It also presents the potential industry supply, market demand, market value, market competition, key market players, and the industry estimate from 2020-2025.

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-tissue-ablation-market-20484

Important Key Questions Answered In The Market Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@researchstore.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@researchstore.bizWeb:www.researchstore.biz

Read more here:
Global Tissue Ablation Market 2020 by Company, Regions, Type and Application, Forecast to 2025Boston Scientific, Abbott, Johnson & Johnson,...

This report includes the overall and comprehensive study of the Opthalmology Pacs market with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the Opthalmology Pacs industry and provides data for making strategies to increase the market growth and effectiveness. The Global Opthalmology Pacs market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Opthalmology Pacs market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Get sample copy of Opthalmology Pacs Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/608

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. In addition to this, regional analysis is conducted to identify the leading region and calculate its share in the global Opthalmology Pacs market. Various factors positively impacting the growth of the Opthalmology Pacs market in the leading region are also discussed in the report. The global Opthalmology Pacs market is also segmented on the basis of types, end users, geography and other segments.

Top Leading Key Players are:

Topcon Corporation, IBM corporation, Carl Zeiss Meditec AG, EyePACS, Heidelberg Engineering and more.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/opthalmology-pacs-market

The research report encourages the readers to comprehend the importance of quality, shortcomings if any and deep investigation for every member independently by giving the global data of great importance about the market. Consequently, the research report presents the organization profiles and deals investigation of the considerable number of vendors which can assist the customers with taking better choice of the products and services. The end clients of the global Opthalmology Pacs market can be sorted based on size of the endeavour. The Research report presents the open doors for the players of the global market. It additionally offers plans of action which can be taken and market conjectures that would be required.

Global Opthalmology Pacs market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

By End-Use, market is segmented into:

HospitalsAmbulatory Surgical Center (ASCS) & Specialty ClinicsOthersBy Type, market is segmented into:

Standalone PACSIntegrated PACSBy Delivery Model, market is segmented into:

Cloud/ web based modelsOn-premise modelsOthers

The research report on global Opthalmology Pacs market ensures users to remain competitive in the market. Also report helps to identify the new innovations and developments by existing key players to increase the growth of the global Opthalmology Pacs market. Study report covers all the geographical regions where competitive landscape exists by the players such as North America, Europe, Latin America, Asia-Pacific and Middle East Africa. Thus report helps to identify the key growth countries and regions.

The study objectives of this report are:To study and analyze the global Opthalmology Pacs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.To understand the structure of Opthalmology Pacs market by identifying its various subsegments.Focuses on the key global Opthalmology Pacs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Opthalmology Pacs with respect to individual growth trends, future prospects, and their contribution to the total market.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).To project the consumption of Opthalmology Pacs submarkets, with respect to key regions (along with their respective key countries).To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.

Key points covered in this report:This report provides pin-point analysis for changing competitive dynamicsIt provides a forward looking perspective on different factors driving or restraining market growthIt provides a six-year forecast assessed on the basis of how the market is predicted to growIt helps in understanding the key product segments and their futureIt provides pin point analysis of changing competition dynamics and keeps you ahead of competitorsIt helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

For Any Query on the Opthalmology Pacs Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/608

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

See more here:
Opthalmology Pacs Market 2020 Global Innovations, Competitive Analysis, New Business Developments and Top Companies Global Forecast to 2026 -...

A new research study from Data Bridge Market Research with title Microbiome Sequencing Insights 2019, Global Analysis and Forecast to 2026 provides an in-depth assessment of the Microbiome Sequencing including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. Some of the leading key players profiled in this study:BIOLOG; Cosmosid Inc; Illumina, Inc.; Metabiomics Corp.; Oxford Nanopore Technologies; BaseClear B.V.; BGI; BioMathematica; Charles River; CoreBiome, Inc.; Clinical-Microbiomics A/S; Diversigen; Eurofins Scientific; LABCYTE INC.; Leucine Rich Bio Pvt Ltd.; Microbiome Insights; MICROBIOME THERAPEUTICS, LLC; Thermo Fisher Scientific Inc.; Molzym GmbH & Co. KG; Norgen Biotek Corp.; Phase Genomics Inc.; QIAGEN; Resphera Biosciences, LLC; Shoreline Biome; StarSEQ GmbH; Viome, Inc.; Zymo Research among others.

Ask For Complimentary Sample PDF| Request Athttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-microbiome-sequencing-market

Global microbiome sequencing marketis expected to rise to an estimated value of USD 3455.33 million by 2026, registering a healthy CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the focus of various researchers on utilization of this technology in the development of personalized medicine and dietary applications.

Key Developments in the Market:

Market Drivers

Market Restraints

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-microbiome-sequencing-market

Segmentation: Global Microbiome Sequencing Market

By Sequencing Technology

By Component

By Targeted Disease

By Application

By Research Type

By End-User

By Laboratory Type

ByGeography

Get Full Table Of content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-microbiome-sequencing-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, and Europe.

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:[emailprotected]

See the original post:
Global Microbiome Sequencing Market Growth Drivers, Demands, Business Opportunities and Demand Forecast to 2026|Clinical-Microbiomics A/S; Diversigen;...

Adenovirus vectors have become a popular delivery platform for gene therapy and vaccines. However, many people have preexisting immunity against adeno-associated viruses (AAVs), which could significantly reduce vector uptake and therefore render the therapeutic cargo they carry ineffective. Even in individuals that lack preexisting immunity, the first inoculation of a vector could induce immune responses that can thwart repeat administration.

To overcome that obstacle, scientists at the University of Pittsburgh created a CRISPR-based system that they say could effectively prevent immunity to the viral vector. The CRISPR tool briefly suppressedgenes that are related to anti-adenovirus antibody production and helped achieve better gene therapy uptake in mice. The results werepublished in Nature Cell Biology.

Samira Kiani, the studys co-senior author, has co-founded SafeGen Therapeutics with the goal to bring this platform to the clinic to enable safer gene therapy.

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

Many clinical trials fail because of the immune response against AAV gene therapy, Kiani said in a statement. And then you cant re-administer the shot because people have developed immunity.

One recent case in point is CanSino Biologics adenovirus type 5 (Ad5)-vectored COVID-19 vaccine. In the shots phase 2 trial, about half of the participants had high levels of preexisting Ad5 neutralizing antibody. These individuals were found to produce significantly lower immune responses to the vaccine than did those with low preexisting anti-Ad5 immunity.

Kiani and colleagues set out to modify the gene expression that's associated with an immune response against AAV, but only temporarilyjust long enough for the therapeutic content to do its jobbecause they didnt want to tamper with normal immune functions.

RELATED:Hopkins team invents non-viral system for getting gene therapy into cells

CRISPR, which can edit out a defective gene or add in a functional one, is already being explored as a gene therapy strategy. So the University of Pittsburgh researchers figured they could hit two birds with one stone by utilizing CRISPR to also control the immune response.

They treated mice with the CRISPR-based system and then re-exposed them to AAV, and the animals didnt make more antibodies against the virus. The treated mice were more receptive to subsequent AAV-delivered gene therapy than were the control animals, the team reported.

Gene therapies hold promise as potential cures to many hard-to-treat diseases that would otherwise require chronic treatment. So scientists have been trying to perfect their transport vehicles for better safety and efficacy.

A team led by scientists at the San Raffaele Telethon Institute for Gene Therapy in Italy, for example,attached the CD47 protein to the surface of lentiviral vectors so they could escape detection and destruction by the immune system. And researchersfrom Johns Hopkins University developed a nonviral delivery system that uses a polymer nano-container, whichreleases the therapy once inside the cell.

Now, Kianihopes to validate the CRISPR-based technology at SafeGen. In addition to its potential as a gene therapy delivery platform, the researchers also found that their method can prevent or treat sepsis in mice, suggesting it might also be useful for treating inflammatory conditions.

Read the original here:
Using CRISPR to improve viral vectors for gene therapy - FierceBiotech

Gene therapy generally relies on viruses, such as adeno-associated virus (AAV), to deliver genes into a cell. In case of CRISPR-based gene therapies, molecular scissors can then snip out a defective gene, add in a missing sequence or enact a temporary change in its expression, but the bodys immune response to AAV can thwart the whole endeavor.

To overcome that obstacle, researchers at the University of Pittsburgh created a system that uses CRISPR in a different way. Their system briefly suppresses genes that are related to AAV antibody production so the virus can deliver its cargo unimpeded. These results published today inNature Cell Biology.Many clinical trials fail because of the immune response against AAV gene therapy, said study co-senior author Samira Kiani, associate professor of pathology in Pitt'sSchool of Medicineand member of thePittsburgh Liver Research Center(PLRC) andMcGowan Institute for Regenerative Medicine. And then you cant readminister the shot because people have developed immunity.

So Kiani and her long-time collaborator Mo Ebrahimkhani, associate professor of pathology at Pitt, member of PLRC and the McGowan Institute, set out to modify gene expression related to the bodys immune response to AAV. But this gene is important for normal immune function, so the researchers didnt want to shut it down forever, just tamp it down momentarily.

Since CRISPR is such a convenient system for editing the genome, the pair figured they would put it to use for altering the master switches that orchestrate genes involved in immune response.

Were hitting two birds with one stone, said Ebrahimkhani. You can use CRISPR to do your gene therapy, and you can also use CRISPR to control the immune response.

When the researchers treated mice with their CRISPR-controlled immune suppression system and then exposed them to AAV again, the animals didnt make more antibodies against the virus. These animals were more receptive to subsequent AAV-delivered gene therapy compared to controls.

Beyond gene therapy, the study also shows that CRISPR-based immune suppression can prevent or treat sepsis in mice, highlighting the potential for this tool to be broadly useful for a range of inflammatory conditions, including cytokine storm andacute respiratory distress syndrome, both of which can crop up with COVID-19, though more studies are needed to engineer safety features.

The main goal of this study was to develop CRISPR-based tools for inflammatory conditions, said study lead author Farzaneh Moghadam, a PhDstudent in Kianis lab. But when we looked at bone marrow samples, we saw that the group treated with our tool showed a lower immune response to AAV compared to the control group. That was very interesting, so we started exploring how this tool contributes to antibody formation against AAV and could potentially address safety and efficacy concerns with gene therapy trials.

Kiani co-founded SafeGen Therapeutics with the goal of bringing this technology to the clinic.

This study was supported by National Institute of Biomedical Imaging and Bioengineering, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, and a DARPA Young Faculty Award.

Reference: Moghadam F, LeGraw R, Velazquez JJ, et al. Synthetic immunomodulation with a CRISPR super-repressor in vivo. Nature Cell Biology. 2020;22(9):1143-1154. doi:10.1038/s41556-020-0563-3.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Continued here:
Editing the Immune Response To Aid the Delivery of Gene Therapy Cargo - Technology Networks

TipRanks

As fears of a tech bubble and stretched valuations become the talk of the town, investors are turning to Wall Street titans for guidance, namely Ken Griffin. Founding hedge fund Citadel in 1990, the firm now boasts over $35 billion worth of assets under management.As a 19-year-old sophomore at Harvard University, Griffin began trading from his dorm room with a fax machine, computer and phone. Now, the CEO of Citadel, whose net worth stands at $15.5 billion, is known as one of the Wall Street greats. Looking at the funds performance during the COVID crisis, its even more clear why Griffin has legendary status.Unlike the average hedge fund, which had a negative return of between 3-4% in the first half of 2020, Citadels flagship Wellington fund saw its returns land between 13-14% for the same period.Bearing this in mind, we wanted to take a closer look at three stocks Citadel snapped up recently. Using TipRanks database, we found out that each ticker has earned a Strong Buy consensus rating from the analyst community. Not to mention all three of them boast massive upside potential.AVEO Pharmaceuticals (AVEO)Hoping to provide better outcomes for patients, AVEO Pharmaceuticals advances targeted medicines for oncology and other unmet medical needs. Following an important regulatory milestone, its no wonder all eyes are on this healthcare name.Griffin is among those singing AVEOs praises. Increasing its holding by a whopping 2,357%, Citadel bought up 383,720 shares in Q2. With the total position now landing at 400,003 shares, it is valued at $1,824,013.H.C. Wainwright analyst Swayampakula Ramakanth reminds investors that on June 1, the FDA accepted the NDA for tivozanib, the company's lead candidate, for review, based on the fact that the TIVO-3 study reported positive final overall survival (OS) data. In the study, AVEOs therapy was compared to sorafenib, marketed as Nexavar by Bayer, for the treatment of advanced renal cell carcinoma (RCC) in the third and fourth-line settings.Looking more closely at the data, which was presented at the ASCO 2020 virtual meeting, the final OS analysis resulted in an overall hazard ratio (HR) of 0.97, which favored tivozanib. Ramakanth was encouraged by the OS results as they suggest tivozanib at least has a similar overall relative risk of deaths compared to sorafenib.Considering that TIVO-3 study met both the primary endpoint of progression free survival (PFS) and the secondary endpoint of overall response rate (ORR), with comparable OS to the active comparator, we believe tivozanib would likely get a green light for the U.S. approval, which could be a major catalyst in the next 12 months, Ramakanth opined.Adding to the good news, the dose escalation for the Phase 1b/2 DEDUCTIVE study, evaluating tivozanib in combination with durvalumab, a monoclonal antibody against PD-L1 marketed as Imfinzi by AstraZeneca in hepatocellular carcinoma (HCC), has been wrapped up, with it progressing to Phase 2. As the CDC estimates about 33,000 patients suffer from liver cancer every year in the U.S., Ramakanth sees an additional opportunity.To this end, Ramakanth rates AVEO a Buy rating along with a $12 price target. Should his thesis play out, a potential twelve-month gain of 163% could be in the cards. (To watch Ramakanths track record, click here)Other analysts dont beg to differ. 3 Buy ratings and no Holds or Sells have been assigned in the last three months. So, the word on the Street is that AVEO is a Strong Buy. The $15 average price target is more aggressive than Ramakanths and implies 229% upside potential. (See AVEO stock analysis on TipRanks)IDEAYA Biosciences (IDYA)Next up we have IDEAYA Biosciences, an oncology-focused precision medicine company that develops targeted therapeutics by using molecular diagnostics. Based on the strength of its technology, this name has scored several fans.Reflecting a new position for Griffin's Citadel, the fund pulled the trigger on 248,005 shares in Q2. As for the value of this holding, it comes in at $2,881,818. Writing for Northland Capital, analyst Tim Chiang believes shares are undervalued based on the future potential of its precision medicine oncology pipeline, which targets specific biomarkers. Expounding on this, he stated, IDEAYA is applying its capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality which represents an emerging class of precision medicine targets.Part of what makes IDYA a stand-out, in Chiangs opinion, is the fact that its preclinical programs use its synthetic lethality (SL) platform, which targets tumors with MTAP gene deletion and homologous recombination deficiency (HRD) including BRCA mutations.We believe the longer-term upside potential with IDYA shares is significant given the potential utility of SL. The first clinically validated SL gene pair was PARP-BRCA1/2, and based on the efficacy of PARP inhibitors, the SL approach to treating cancer has achieved substantial commercial validation, the analyst explained.To back this up, Chiang points out that several PARP inhibitors have already been approved for the treatment of tumors with BRCA and other DNA damage repair alterations, including ovarian, breast and pancreatic cancers. These inhibitors include AstraZeneca's olaparib, GlaxoSmithKline's niraparib, Pfizer's talazoparib and Clovis rucaparib. He added, We estimate these four drugs generated over $1.6 billion in worldwide sales in 2019 and are expected to reach over $6 billion in sales by 2024.It should be noted that multiple IND filings are set to come within the next 4-12 months, with IDYAs lead SL candidate, IDE397, which was designed to inhibit MTAP and MAT2A and thus cause the death of cancerous tumor cells, entering the clinic in 2021.It should come as no surprise, then, that Chiang joined the bulls. To start off his IDYA coverage, he puts an Outperform rating and $28 price target on the stock. This target implies a possible twelve-month rise of 141% could be on the horizon. (To watch Chiangs track record, click here)Similarly, the rest of the Street is getting onboard. 5 Buy ratings assigned in the last three months add up to a Strong Buy analyst consensus. In addition, the $25.20 average price target puts the potential twelve-month gain at 116%. (See IDYA stock analysis on TipRanks)Ocular Therapeutix (OCUL)Using its patented bioresorbable hydrogel-based formulation technology, Ocular Therapeutix develops cutting-edge therapies for diseases and conditions of the eye. The progress of its clinical programs has caught Wall Streets attention, with some arguing that now is the time to get in on the action.Griffin and Citadel didnt want to miss out on an opportunity. Snapping up 161,032 shares during Q2, the hedge fund gave the holding a 272% boost. The total position is now comprised of 220,269 shares and is valued at $1,718,098.Representing Raymond James, 5-star analyst Dane Leone cites the potential to address the unmet needs in the dry eye disease indication as a key component of his bullish thesis. The company boasts two assets targeting the condition, OTX-CSI (chronic) and OTX-DED (acute). OTX-CSI incorporates the FDA-approved immunomodulator cyclosporine as the active drug in the intracanalicular insert, which is released for an estimated three months to increase tear production.When it comes to OTX-DED, Leone argues OCUL was clever in pursuing the development of OTX-DED (a low dose form of DEXTENZA, a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus to deliver dexamethasone to the ocular surface for up to 30 days without preservatives) for the treatment of episodic dry eye, as the prior safety data from the DEXTENZA approval enabled management to file a Phase 2-enabling IND by YE20.Speaking to the possible opportunity here, both products could provide revenue generation for physicians in the treatment of dry eyes using procedure CPT code 0356T, which could provide incentive for rapid adoption in the dry eye space that is currently valued at $5.1 billion, in Leones opinion.As for the clinical and regulatory pathway, the Phase 2 trial for OTX-DED is set to kick off in 2H21, slightly after OTX-CSI, which will see a Phase 2 clinical trial evaluating two different formulations initiated by 4Q20. Based on the short treatment duration of OTX-DED, management thinks it will still be brought to market first.To this end, Leone remains optimistic about the companys long-term growth narrative. As a result, he rates OCUL a Strong Buy along with a $15 price target. This figure implies shares could rise 89% in the year ahead. (To watch Leones track record, click here) Turning now to the rest of the Street, other analysts are on the same page. With 100% Street support, or 3 Buy ratings to be exact, the consensus is unanimous: OCUL is a Strong Buy. The $13.50 average price target brings the upside potential to 70%. (See OCUL stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Link:
Global Gene Therapy Market is Forecast to Reach US$ 6.42 billion in 2024, Witnessing Growth at a CAGR of 19.29% Over 2020-2024 - Yahoo Finance

Gyros Protein Technologies AB has announced the introduction of Gyrolab AAVX Titer Kit for adeno-associated virus (AAV) vector titer determination in AAV vector manufacturing. The new Gyrolab AAVX Titer Kit for physical titer determination, one of the critical quality attributes (CQAs) of the FDA process validation guidelines, has a broad applicability across numerous AAV serotypes and adds to the Companys wide range of ready-to-use kits that are already used by scientists and bioengineers in the rapidly growing cell and gene therapy market, where AAV vectors are commonly used.

Gyrolab AAVX Titer Kit supports scientists in the development and production of cell and gene therapies to maximize performance and productivity, and reduces the time needed to produce patient treatments. With compressed development timelines for these therapies, the new kit generates results 4 times faster and requires 10 times less sample compared to traditional ELISA methods, accelerating AAV vector workflows and enabling high quality data to be produced from small sample volumes. Featuring an analytical range of >3 logs, Gyrolab AAVX Titer Kit also minimizes repeat testing compared to ELISA.

Gyrolab AAVX Titer Kit is based on a highly selective AAVX affinity ligand developed with the Thermo Scientific CaptureSelect technology by Thermo Fisher Scientific. These ligands are also the basis of POROS CaptureSelect AAVX Affinity Resin, which is frequently used to purify AAV viral vectors. The AAVX ligand binds with high affinity and selectivity to native and recombinant AAV particles of various serotypes (AAV1 to AAV8, AAVrh10).

Read more:
Gyrolab AAVX Titer Kit Introduced to Support Cell and Gene Therapy Market - Technology Networks